Lorundrostat Open-Label Extension Study

Study Overview

An open-label extension evaluating long-term safety and blood pressure-lowering efficacy of lorundrostat, an aldosterone synthase inhibitor, in adults with uncontrolled hypertension who completed prior lorundrostat parent trials.

Inclusion Criteria

• ✓Adults aged 18 years or older
• ✓Completed a prior lorundrostat parent study (MLS-101-202, -206, or -301)
• ✓Fertile subjects must use acceptable contraception
• ✓Maintained ≥75% compliance with study medication in parent study

Exclusion Criteria

• ✗Pregnant, planning pregnancy, or breastfeeding
• ✗Use of prohibited medications (potassium-sparing diuretics, strong CYP3A4 inhibitors)
• ✗Serum potassium >5.5 mmol/L at baseline
• ✗Any condition precluding safe participation per Investigator judgment